NCT04292964

Completed

Prognostic Factors of Patients With COVID-19

Chongqing Medical University Source

Other study identifiers

Sponsor study identifier

2020-02-2

Study Type

observational

Actual enrollment (reported)

201

Locations

1 country

Sites

1

Timeline

Study Start

March 1, 2020

Actual (reported)

Primary Completion

March 13, 2020

Actual (reported)

Study Completion

March 13, 2020

Actual (reported)

Brief Summary

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. Despite lower mortality rate, SARS-CoV-2 has killed more people than SARS and MERS and the number keeps growing. Epidemic studies have been well described clinical features of patients with COVID-19, with the disease severity being an independent predictor of poor outcome. However, there is still no research investigating the prognostic factors of patients with COVID-19.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 201 participants
Study completion date: March 13, 2020
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
March 1, 2020
Actual (reported)
Study Start
March 1, 2020
Actual (reported)
First Posted
March 3, 2020
Actual (reported)
Primary Completion
March 13, 2020
Actual (reported)
Study Completion
March 13, 2020
Actual (reported)

Last Updated: March 17, 2020
Status Verified: March 2020
Last Update Submitted: March 13, 2020

Conditions

Outcome, Fatal SARS-CoV-2

Outcome Measures

Primary Outcomes (1)

all-cause mortality
30 days

Secondary Outcomes (2)

all-cause mortality
15 days
Severe state
15 days

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients with COVID-19

You may qualify if:

Adult aged \>=18years old;

Sponsors & Collaborators

Chongqing Medical University
Otherlead

Study Sites (1)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, China

Related Publications (2)

Wen XS, Jiang D, Gao L, Zhou JZ, Xiao J, Cheng XC, He B, Chen Y, Lei P, Tan XW, Qin S, Zhang DY. Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study. BMC Infect Dis. 2021 Jan 12;21(1):57. doi: 10.1186/s12879-020-05741-w.
PMID: 33435865DERIVED
Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, You LN, Lei P, Tan XW, Qin S, Cai GQ, Zhang DY. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020 Apr 15;21(1):83. doi: 10.1186/s12931-020-01352-w.
PMID: 32293449DERIVED

Enrollment

201 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Clinical Professor

Study Record Dates

First Submitted

March 1, 2020

First Posted

March 3, 2020

Study Start

March 1, 2020

Actual (reported)

NCT04443257

REassessement After Hospitalization for Sars-COV-2 disordER

Terminated

NCT04367207

African Covid-19 Critical Care Outcomes Study

Unknown

NCT04252664

A Trial of Remdesivir in Adults With Mild and Moderate COVID-19

Phase 3Suspended

NCT05903118

A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults

Phase 1/2Completed

NCT04359706

Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19

Completed

NCT04414241

Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19

Phase 3Completed

Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed SARS-Cov-2 infection; CT of the lung conformed to the manifestation of viral pneumonia.

Criteria for severe or critical ill conditions: Respiratory rate \>=30/min; or Rest SPO2\<=93%; or PaO2/FiO2\<=300mmHg.

You may not qualify if:

Near-death state (expected survival time less than 24 hours);
Malignant tumor;
Pregnancy or puerperium women;
Patients who refused to participant.

Contact the study team to confirm eligibility.

Primary Completion

March 13, 2020

Actual (reported)

Study Completion

March 13, 2020

Actual (reported)

Last Updated

March 17, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT04292964
Data provider: ClinicalTrials.gov
Source updated: 2020-03-17
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:27:05 UTC

Locations

CN(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (2)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations